Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Cash from Operations: 2017-2019

Historic Cash from Operations for Astria Therapeutics (ATXS) over the last 3 years, with Dec 2019 value amounting to -$7.8 million.

  • Astria Therapeutics' Cash from Operations fell 47.47% to -$7.8 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$26.6 million, marking a year-over-year decrease of 13.23%. This contributed to the annual value of -$81.2 million for FY2024, which is 18.65% down from last year.
  • As of Q4 2019, Astria Therapeutics' Cash from Operations stood at -$7.8 million, which was down 20.02% from -$6.5 million recorded in Q3 2019.
  • In the past 5 years, Astria Therapeutics' Cash from Operations registered a high of -$5.3 million during Q4 2018, and its lowest value of -$8.1 million during Q1 2017.
  • In the last 3 years, Astria Therapeutics' Cash from Operations had a median value of -$6.1 million in 2018 and averaged -$6.4 million.
  • As far as peak fluctuations go, Astria Therapeutics' Cash from Operations rose by 22.11% in 2018, and later crashed by 47.47% in 2019.
  • Astria Therapeutics' Cash from Operations (Quarterly) stood at -$5.6 million in 2017, then grew by 6.53% to -$5.3 million in 2018, then tumbled by 47.47% to -$7.8 million in 2019.
  • Its Cash from Operations stands at -$7.8 million for Q4 2019, versus -$6.5 million for Q3 2019 and -$5.7 million for Q2 2019.